Thomas E Stinchcombe Selected Research

Thomas E Stinchcombe Research Topics

Disease

86	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 06/2022 - 12/2004
43	Neoplasms (Cancer) 06/2022 - 03/2005
16	Lung Neoplasms (Lung Cancer) 01/2022 - 04/2005
15	Disease Progression 01/2022 - 01/2008
12	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2021 - 04/2005
7	Leukemia 07/2017 - 11/2008
6	Neutropenia 11/2020 - 04/2005
5	Fatigue 01/2021 - 11/2002
5	Exanthema (Rash) 12/2020 - 04/2005
4	Adenocarcinoma 06/2022 - 06/2012
4	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2021 - 12/2013
4	Hematologic Neoplasms (Hematological Malignancy) 01/2021 - 11/2002
4	Diarrhea 12/2020 - 04/2005
4	Neoplasm Metastasis (Metastasis) 11/2019 - 11/2006
3	Thrombocytopenia (Thrombopenia) 01/2021 - 11/2002
3	Hypertension (High Blood Pressure) 10/2019 - 04/2009
3	Brain Neoplasms (Brain Tumor) 05/2013 - 04/2009
3	Hypersensitivity (Allergy) 08/2007 - 11/2002
2	Cardiotoxicity 01/2022 - 05/2017
2	Carcinoma (Carcinomatosis) 01/2021 - 07/2017
2	Ovarian Neoplasms (Ovarian Cancer) 01/2021 - 10/2007
2	Anemia 11/2020 - 01/2017
2	Malignant Mesothelioma 11/2020 - 01/2017
2	Mucositis 01/2017 - 04/2005
2	Breast Neoplasms (Breast Cancer) 10/2007 - 08/2007
1	Lymphoma (Lymphomas) 01/2022
1	Heart Diseases (Heart Disease) 01/2022
1	Cardiovascular Diseases (Cardiovascular Disease) 01/2022
1	Central Nervous System Diseases (CNS Diseases) 01/2021
1	Lymphopenia (Lymphocytopenia) 11/2020
1	Virus Diseases (Viral Diseases) 01/2020
1	COVID-19 01/2020
1	Proteinuria 10/2019

Drug/Important Bio-Agent (IBA)

15	Carboplatin (JM8)FDA LinkGeneric 01/2021 - 02/2006
14	PlatinumIBA 09/2021 - 04/2005
12	Paclitaxel (Taxol)FDA LinkGeneric 01/2021 - 03/2005
11	Pemetrexed (MTA)FDA Link 11/2020 - 04/2005
10	ErbB Receptors (EGF Receptor)IBA 10/2019 - 09/2008
9	Bevacizumab (Avastin)FDA Link 10/2019 - 09/2007
8	Biomarkers (Surrogate Marker)IBA 02/2022 - 10/2009
8	Tyrosine Kinase InhibitorsIBA 01/2022 - 10/2011
7	Erlotinib Hydrochloride (CP 358,774)FDA Link 10/2019 - 09/2011
5	Gemcitabine FDA Link 04/2013 - 03/2005
5	Gefitinib (Iressa)FDA Link 06/2012 - 06/2006
5	Docetaxel (Taxotere)FDA Link 09/2008 - 04/2005
4	Immune Checkpoint InhibitorsIBA 01/2022 - 03/2015
4	Pharmaceutical PreparationsIBA 05/2017 - 12/2004
3	B7-H1 AntigenIBA 06/2022 - 07/2017
3	pembrolizumabIBA 06/2022 - 08/2021
3	Circulating Tumor DNAIBA 01/2022 - 10/2019
3	osimertinibIBA 01/2021 - 02/2016
3	Cetuximab (Erbitux)FDA Link 12/2020 - 08/2007
3	Etoposide (VP 16)FDA LinkGeneric 01/2019 - 02/2011
3	Anaplastic Lymphoma KinaseIBA 01/2016 - 01/2011
3	Albumin-Bound Paclitaxel FDA Link 02/2015 - 10/2007
2	brigatinibIBA 01/2022 - 01/2021
2	LigandsIBA 01/2022 - 01/2020
2	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2022 - 01/2021
2	NivolumabIBA 09/2021 - 03/2015
2	Immunoconjugates (Immunoconjugate)IBA 01/2021 - 12/2017
2	Messenger RNA (mRNA)IBA 01/2021 - 01/2017
2	Cell-Free Nucleic AcidsIBA 10/2019 - 01/2019
2	Immunoglobulin G (IgG)IBA 07/2017 - 03/2015
2	Sunitinib (Sutent)FDA Link 01/2017 - 02/2014
2	Monoclonal AntibodiesIBA 01/2014 - 11/2010
2	vinflunineIBA 10/2011 - 02/2011
2	Cisplatin (Platino)FDA LinkGeneric 02/2011 - 11/2008
2	SolventsIBA 05/2008 - 10/2007
2	130-nm albumin-bound paclitaxelIBA 05/2008 - 08/2007
2	Irinotecan (Camptosar)FDA LinkGeneric 03/2008 - 09/2007
1	atezolizumabIBA 06/2022
1	alectinibIBA 01/2022
1	niraparibIBA 01/2022
1	Histocompatibility Antigens Class IIBA 10/2021
1	IpilimumabIBA 09/2021
1	navitoclaxIBA 01/2021
1	durvalumabIBA 01/2021
1	telisotuzumab vedotinIBA 01/2021
1	tremelimumabIBA 01/2021
1	veliparibIBA 01/2021
1	Polytetrafluoroethylene (Teflon)FDA Link 01/2021
1	talazoparibIBA 01/2021
1	Gonadotropin-Releasing Hormone (GnRH)FDA Link 01/2021
1	AfatinibIBA 12/2020
1	tributyl phosphate (TBP)IBA 01/2020
1	Interferon-gamma (Interferon, gamma)IBA 01/2020
1	Ado-Trastuzumab EmtansineIBA 01/2019
1	Toll-Like Receptors (Toll-Like Receptor)IBA 11/2018

Therapy/Procedure

49	Therapeutics 06/2022 - 11/2002
28	Drug Therapy (Chemotherapy) 09/2021 - 02/2006
21	Radiotherapy 01/2022 - 07/2006
8	Immunotherapy 02/2022 - 05/2014
8	Chemoradiotherapy 01/2021 - 09/2009
5	Combined Modality Therapy 01/2019 - 04/2006
4	Induction Chemotherapy 09/2017 - 03/2008
3	Adjuvant Chemotherapy 01/2022 - 09/2007
2	Cranial Irradiation 01/2019 - 07/2010
2	Conformal Radiotherapy 11/2011 - 01/2009
2	Maintenance Chemotherapy 10/2009 - 02/2009
1	Lymph Node Excision (Lymph Node Dissection) 01/2022